feasibility of treatment cessation in patients with cml with atypical bcr-abl fusion transcripts
Published 2 years ago • 206 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
2:26
feasibility of sequential treatment with cd19-targeted agents in patients with lbcl
-
1:56
the feasibility of chemotherapy-free regimens without allogeneic transplantation in mrd- ph all
-
1:34
feasibility of the ipss-m in cmml
-
2:26
feasibility of second cart19 administration with rituximab-based lymphodepletion in r/r b-all
-
2:41
cell avidity as a predictor of t-cell efficacy
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
7:46
updates in aml treatment and research from asco 2023
-
25:59
raven leukapheresis processing training video
-
2:19
feasibility of biomarker-driven strategy in high-risk lbcl: final results from nordic phase ii study
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:59
tangible benefit for flt3-itd r/r aml on quizartinib
-
4:02
testing for bcr::abl kinase mutations in cml and how they impact tki resistance
-
0:43
the development of a composite comorbidity index to predict car-t outcomes in patients with dlbcl
-
2:31
updates in the diagnosis, risk stratification & treatment of aml: who, icc, and eln classifications
-
1:28
the role of allogeneic transplantation in patients with aml in the frontline setting
-
1:34
personalizing treatment of transfusion-dependent anemia in lr-mds
-
6:50
improving the management of patients with newly diagnosed aml presenting with hyperleukocytosis
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
3:25
how have leukemia diagnostics and management evolved?
-
1:52
the management of r/r flt3-mutated aml
-
2:35
how molecular testing guides treatment in aml
-
3:23
patient characteristics and outcomes of allosct for bpdcn